Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 30 May 2016 - On 3 February 2016, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 3 February 2016.
Under the programme initiated 29 April 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 29 April 2016 to 3 August 2016.
Since the announcement as of 19 May 2016, the following transactions have been made under the programme:
| Number of B shares |
Average purchase price |
Transaction value, DKK |
|
| Accumulated, last announcement | 1,642,000 | 587,842,892 | |
| 19 May 2016 | 160,000 | 358.51 | 57,362,224 |
| 20 May 2016 | 158,000 | 359.30 | 56,768,768 |
| 23 May 2016 | 145,000 | 356.92 | 51,753,226 |
| 24 May 2016 | 150,000 | 361.06 | 54,158,385 |
| 25 May 2016 | 145,000 | 375.17 | 54,400,201 |
| 26 May 2016 | 150,000 | 373.18 | 55,977,090 |
| 27 May 2016 | 140,000 | 371.46 | 52,004,610 |
| Accumulated under the programme | 2,690,000 | 970,267,396 |
With the transactions stated above, Novo Nordisk owns a total of 14,767,645 B shares of DKK 0.20, corresponding to 0.6% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 3 February 2016. As of 27 May 2016, Novo Nordisk has repurchased a total of 12,836,000 B shares equal to a transaction value of DKK 4,599,822,121.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 3079 3450 | amhg@novonordisk.com |
| Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
| Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Company announcement no 43 / 2016
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
HUG#2016462
\Hugin